Back to Report Store Home

Global Neurodegenerative Drugs Market to 2022 – Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • Published: Dec-2016
  • Report Code: GBIHC425MR
  • Report Format: pdf

Description

List of Tables

Table 1: Neurodegenerative Disorders Therapeutics Market, Symptoms of AD, PD, HD, ALS and MS, 2016 14

Table 2: Neurodegenerative Disorders Therapeutics Market, Etiology of AD, PD, HD, ALS and MS, 2016 16

Table 3: Neurodegenerative Disorders , Global, Epidemiology of Neurodegenerative Disorders, 2016 23

Table 4: Neurodegenerative Disorders Therapeutics Market, Comorbidities Associated with AD, PD, HD, ALS and MS, 2016 29

Table 5: Neurodegenerative Disorders Therapeutics Market, Treatment Options Available for Parkinson’s Disease, 2016 31

Table 6: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tecfidera, 2016 36

Table 7: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Copaxone, 2016 38

Table 8: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tysabri, 2016 40

Table 9: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Gilenya, 2016 41

Table 10: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Avonex, 2016 43

Table 11: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Plegridy, 2016 45

Table 12: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Namenda/Namenda XR, 2016 47

Table 13: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Nuplazid, 2016 48

Table 14: Neurodegenerative Disorders, Global, Annual Revenue for key Products ($bn), 2015–2022 83

Table 15: Neurodegenerative Disorders, Global, Revenue by Company, 2015–2022 90

Table 16: Neurodegenerative Disorders, Global, Licensing Deals Valued above $100m, 2006–2016 112

Table 17: Neurodegenerative Disorders, Global, Co-development Deals Valued above $100m, 2006–2016 120

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards